Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tirzepatide + mibavademab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous
01
Overview
This is a **combination of two investigational drugs: tirzepatide and mibavademab**, currently studied for obesity. Tirzepatide is a dual **glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide 1 (GLP-1) receptor agonist**, while mibavademab is an investigational monoclonal antibody. The main purpose of the combination is to assess whether adding mibavademab to tirzepatide can enhance weight loss in adults with obesity compared with tirzepatide alone. The combination is administered subcutaneously and is currently being evaluated in Phase 2 clinical trials[1][2][3][4][5][7].
- Other names
- tirzepatide + mibavademab
02
Targets
Beyond the preview
Go deeper on tirzepatide + mibavademab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tirzepatide + mibavademab.